

HEMATOLOGIE 2026 - SCHÉMA ODBORNÉHO PROGRAMU

Legenda

EDUKAČNÍ SDĚLENÍ
ORÁLNÍ SDĚLENÍ
MEET THE EXPERT WORKSHOPY
SLAVNOSTNÍ PROGRAM + JOINT SYMPOSIUM EHA / CSH
OŠETŘOVATELSKÝ PROGRAM

STŘEDA 21. 1. 2026

1. den	sál ZENIT + NADIR	sály TYCHO + KEPLER	sál Aquarius
8:00 - 18:00	Registrace		
8:30 - 10:45			9:00 - 10:45 Statistický workshop Vydra J., Pecherková P. (Praha)
11:00 - 12:45	Odborný program - Blok I	x	
	Předsednictvo: Gumulec J. (Ostrava), Starý J. (Praha)		
	E01 Blatný J. (Brno): Co bychom měli vědět o léčbě hemofilie v roce 2026?		
	E02 Dulíček P. (Hradec Králové): Riziko venózního tromboembolizmu u nemocných s lymfomem		
	O01 Havránek O. (Praha): (ID 83): Multiple Reciprocal Interactions within B-cell Receptor and AKT Signaling Pathways Regulate Response to EZH2 Inhibition in Germinal Center-derived Diffuse Large B-cell Lymphoma		
	O02 Mráz M. (Brno): (ID 14): Repression of miR-29 via MYC Leads to Increased CD40 Signaling in Transformed Follicular Lymphoma		
	O03 Mejstříková E. (Praha): (ID 79): Clonal dynamics of T cells and treatment outcomes in Pediatric Lymphocytic variant Eosinophilic syndrome		
	E03 Horváthová M. (Olomouc): Vrozené erytrocytózy		
12:45 - 13:15	Rozšířený coffee break		
13:15 - 15:00	Odborný program - Blok II	x	
	Předsednictvo: Machová K. (Praha), Žáčková D. (Brno)		
	E04 Láníková L. (Praha): Vrozené mutace a myeloidní nádory		
	O04 Hlušíčková Kaprálová K. (Olomouc) (ID 18): JAK2 R1063H GERMLINE VARIANT IN AML: ASSOCIATION WITH ONCOGENIC IDH1/2 DRIVERS RESULTING IN COOPERATIVE LEUKEMOGENESIS AND THERAPEUTIC IMPLICATIONS		
	O05 Mayer J. (Brno): (ID 11): CHRONIC MYELOID LEUKEMIA (CML) TREATMENT DISCONTINUATION AFTER A TWO-STEP DOSE REDUCTION. THE FIRST RESULTS OF THE PHASE 2 STUDY HALF.		
	O06 Machová K. (Praha): (ID 32): DNA-based MRD monitoring enhances risk stratification during TKI dose reduction in CML: Evidence from the clinical trial		
	E05 Jonášová A., Rusinová K. (Praha): Co vše patří do paliativní péče?		
	E06 Folber F. (Brno): Nežádoucí účinky CAR T-cell terapie a bispec. protilátek		
15:00 - 15:30	Coffee break		

15:30 17:30	SLAVNOSTNÍ ZAHÁJENÍ Heřmanského přednáška: Steven Treon (USA): Genomics and Treatment in Waldenstrom's Macroglobulinemia Neuwirtova přednáška: Naoki Hosen (Japan): Novel CAR T/NK Cell Therapies	x
17:45 - 19:00	Posterová sekce (sál Meridian)	
od 19:00	Diskuse u posterů a večeře (sál Meridian a foyer)	

ČTVRTEK 22. 1. 2026

2. den	sál ZENIT + NADIR	sály TYCHO + KEPLER	sály Leo + Virgo	sály Aquarius + Taurus
8:00 - 18:00	Registrace			
8:30 - 9:15	Satelitní sympozium CSL Behring	Satelitní sympozium Gilead		
9:30 - 10:30	x	Meet the expert workshop 1 - How I treat Waldenstrom macroglobulinemia Steven Treon Moderace: M. Trněný	Meet the expert workshop 2 - Konzumpční koagulopatie v klinické praxi Peter Salaj	Meet the expert workshop 3 - "Výživové mýty pod lupou: Praktický průvodce populárními otázkami" Adam Obr, David Erban (Praha)
10:30 - 11:00	Coffee break			
11:00 - 12:45	Odborný program - Blok III	11:00 - 12:30 Ošetřovatelský program I. - "Infekce pod kontrolou" edukační program		
	Předsednictvo: Jindra P. (Plzeň), Šrámková L. (Praha)	Předsednictvo: Vylitová L. (Praha), Wintnerová J. (Praha)		
	E07 Šálek C. (Praha): Akutní lymfoblastová leukémie	ES01 Hrončková J. (Praha): Standardní a cílená protiepidemická opatření na pracovištích Kliniky dětské hematologie a onkologie 2.LF UK a FN Motol z pohledu Oddělení nemocniční hygieny a epidemiologie		
	O07 Ševčíková T. (Ostrava): (ID 64): ELEVATED CIRCULATING TUMOR CELL (CTC) NUMBERS ASSOCIATE WITH A HIGHLY PROLIFERATIVE (PR) AND GENOMICALLY COMPLEX PHENOTYPE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS	ES02 Čermáková J. (Praha): Sepse u dětských hematoonkologických pacientů – závažná komplikace léčby		
	O08 Venglář O. (Ostrava): (ID 61): Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8 color flow cytometry panel reveals substantial differences among products kinetics and persistence	ES03 Labská K. (Praha): Hygienické režimy a zkušenosti s jejich aplikací v ÚHKT		
	O09 Kuba A. (Olomouc): (ID 107): Immune and DNA-damage responses in the intestinal stroma of patients presenting with lower gastro-intestinal symptoms after allogeneic stem cell transplantation	ES04 Hráčková H. (Praha): Jak chránit planetu a neohrozit pacienta?		
	E08 Marková M. (Praha): Alogenní transplantace – myelodysplastický syndrom	12:35 - 13:15 Vzdělávací seminář: Jak zjednodušit práci sestry a život hematoonkologickým pacientům se sekundární imunodeficiencí Milota T. : Sekundární imunodeficiency – základy diagnostiky a léčby v hematoonkologii (15 min.) Henebergová D.: Cesta k lepší spolupráci pacienta - imunoglobulinová léčba krok za krokem (20 min.)		
	E09 Novák J. ; Racková M. (Praha): Potransplantační lymfoproliferace			
12:30 - 13:45	Oběd			
13:45 - 14:30	13:30 - 14:30 Satelitní sympozium Novartis		13:45 - 14:30 Satelitní sympozium Johnson&Johnson	

14:45 - 16:15	Blok IV - Joint symposium EHA / CSH	14:00 - 15:30 Ošetřovatelský program II. - Workshop: "Jak se dělá duševní zdraví" Světlák M. (Brno)
	<i>Předsednictvo: Döhner K. (Ulm; Germany); Žák P. (Hradec Králové)</i>	
	Döhner K. (Ulm; Germany): Perspectives on Current Diagnosis and Follow-up Strategies in Adult AML Patients	
	Ilan U. (Utrecht; NL): AI in hematology	
	Jelínek T. (Ostrava): Multiple myeloma in 2026 and Beyond	
16:15 - 16:45	Coffee break	
16:45 - 18:15	Odborný program - Blok V - Best of papers / best of abstracts	16:00 - 17:30 1. patientský seminář nejen pro pacienty - Onkopsychologie Pospíchal M. (Praha)
	<i>Předsednictvo: Cetkovský P. (Praha), Zuna J. (Praha)</i>	
	<i>Paper uvede: Špaček M. (Praha)</i>	
	BP01 Pavlová Š. (Brno): Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL	
	<i>Paper uvede: Šálek C. (Praha)</i>	
	BP02 Šeferna K. (Praha): NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk	x
	Oceněná sdělení mladých hematologů:	
	<i>Uvede: Procházka V. (Olomouc)</i>	
	O10 Vodička P. (Praha): Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts	
	<i>Uvede: Stopka T. (Praha)</i>	
	O11 Shaikh M. (Praha): Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance in AML, revealing a potential treatment strategy co-targeting ALDH1A inhibition with hypomethylating agents	
18:30-19:15	Satelitní sympozium	Satelitní sympozium
19:30	Večeře	

PÁTEK 23. 1. 2026

3. den	sál ZENIT + NADIR	sály TYCHO + KEPLER	sály Leo + Virgo
8:00 - 13:30	<i>Registrace</i>		
8:30 - 9:15	Satelitní sympozium	x	Satelitní sympozium Swixx Biopharma
9:30 - 10:15	Satelitní sympozium	9:00 - 10:30 Ošetřovatelský program III. - Workshop: Komunikační dovednosti s mediačním nástrojem - Absolonová P. (Brno)	x

10:15 - 11:00	10:15 - 10:30 Přestávka	10:30 - 11:00 Přestávka	
10:30 - 11:30	Meet the expert workshop 4 - MRD in AML - <i>Konstanze Döhner</i> Moderace: J. Trka	11:00 - 13:00 Ošetrovatelský program IV. - VARIA	Meet the expert workshop 5 - AI in hematology <i>Uri Ilan</i> Moderace: J. Zuna
11:30 - 12:00	Přestávka	Předsednictvo: Hrabánková D. (Praha), Turková L. (Praha)	
12:00 - 13:30	Odborný program - Blok VI	S01 Růžičková L. (Praha): „Jídlo jako lék“	
	Předsednictvo: Kozák T. (Praha), Papajík T. (Olomouc)	S02 Malyszková K. (Ostrava): Uzdrav mysl - Mindfullnes	
	E10 Klener P. (Praha): Novinky v diagnostice a léčbě DLBCL- postASH	S03 Vondrová M. (Praha): „Aromaterapie k duševní harmonii“	
	E11 Šimkovič M. (Hradec Králové): Praktický přístup k léčbě CLL: současné možnosti a jejich optimální využití	S04 Wintnerová J. (Praha): Jak dopadl projekt „Prevence syndromu vyhoření“ na Klinice dětské hematologie a onkologie?	
	O12 Vodička P. (Praha): (ID 53): Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients	S05 Vedrová J. (Praha): Fytoterapie a koření v hematoonkologii – vliv na účinnost léčby	
	O13 Trněný M. (Praha): (ID 45): Tafasitamab (tafa) plus Lenalidomide (len) and Rituximab (R) for Patients With Relapsed or Refractory Follicular Lymphoma (R/R FL): Results from the Phase 3 inMIND Study	S06 Koňářík M. (Ostrava): Od stigmat k standardům - konopí v moderní ošetrovatelské péči	
	E12 Sýkorová A. (Hradec Králové): Hodgkinův lymfom 2025: Klíčová sdělení	S07 Keslová P. (Praha): Bertíkovo uzdravení jako nástroj pro komunikaci závažné diagnózy u dětí nízkého věku s onkologickým onemocněním	
13:30	ZAKONČENÍ KONFERENCE A OBĚD		

Posterová sekce

Moderovaná diskuse: středa 21. 1. 2026 od 17:45 hodin (sál Meridian)

AKUTNÍ LEUKÉMIE (Postery P01 - P11)

P01	Kolárik M. (Praha) a spol.	L-asparaginase alters redox homeostasis in acute lymphoblastic leukemia	<i>EHA 2025</i>
P02	Palavandishvili N. (Praha) a spol.	Monocytic Switching in DUX4-Positive BCP-ALL: Challenges in MRD Assessment and Prognostic Impact	<i>other</i>
P03	Palavandishvili N. (Praha) a spol.	Surface protein profiling of childhood B-cell precursor acute lymphoblastic leukemia	<i>other</i>
P04	Starková J. (Praha) a spol.	High metabolic activity in leukemic cells is associated with more aggressive phenotype and reduced treatment efficacy	<i>EHA 2025</i>
P05	Kužílková D. (Praha) a spol.	Investigating Prednisone-Induced Signaling Pathway Changes in Pediatric T-ALL	<i>EHA 2025</i>
P06	Polívková V. (Praha) a spol.	Implementation of Extended Molecular Diagnostics in the Clinical Management of Adult ALL Patients	<i>4th Translational Research Conference: Acute Lymphoblastic Leukaemia (ESH)</i>
P07	Křížková J. (Praha) a spol.	Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL)	<i>ASH 2025</i>
P08	Lázníčka A. (Praha) a spol.	ACUTE TOXICITIES DURING INDUCTION AND FIRST CONSOLIDATION TREATMENT OF YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: COMPARISON OF ALL CELL 2023 JUNIOR AND GMALL 07/2003 PROTOCOLS – A SINGLE CENTER EXPERIENCE	<i>CLEAR 2025</i>
P09	Dvořáčková B. (Brno) a spol.	Analýza genomových aberací u dospělých pacientů s akutní lymfoblastickou leukémií pomocí sekvenování dlouhým čtením	
P10	Hrabovský Š. (Brno) a spol.	Brexucabtagene autoleucel v léčbě akutní lymfoblastové leukémie – pilotní analýza CELL a srovnání s daty mezinárodních souborů	
P11	Štach M. (Praha) a spol.	CD19 Chimeric Antigen Receptor-T Cells with Enhanced Tscm Immunophenotype produced by piggyBac transposon system for Therapy of Refractory B-cell Malignancies- Preliminary Results of Phase I Clinical Trial	<i>EHA 2025</i>

AKUTNÍ MYELOIDNÍ LEUKÉMIE I. (Postery P12 - P19)

P12	Dudičová S. (Hradec Králové) a spol.	FLT3 INHIBITORS MIDOSTAURIN AND GILTERITINIB ENHANCE CYTARABINE ACCUMULATION BY AFFECTING OCTN1 AND ENT1 TRANSPORTERS IN AML CELLS	EHA 2025
P13	Čečková M. (Hradec Králové) a spol.	IDENTIFICATION OF CELLULAR MECHANISMS THAT CAN LEAD TO DRUG RESISTANCE TO FLT3 INHIBITOR GILTERITINIB IN AML	EHA 2025
P14	Cerovská E. (Praha) a spol.	Integrative analysis of the interplay between peripheral immune landscape and leukemic blast adaptation in acute myeloid leukemia	ASH 2025
P15	Rataj J. (Hradec Králové) a spol.	Evaluation of novel structures as potential FLT3 inhibitors in AML	EHA 2025
P16	Plešingerová H. (Brno) a spol.	Analysis of AML cells in vitro: Sensitivity to CK1 inhibition vs. genetic background	13th International Conference Analytical Cytometry
P17	Kořánová T. (Praha) a spol.	PD-L1 expression on leukemia cells is dynamic and correlates with glycolytic rate	ESH 2025
P18	Mendlíková I. (Praha) a spol.	Neocentromeres in complex acute leukemia karyotypes as an indicator of chromosomal instability and disease progression	15th European Cytogenomics Conference
P19	Jarošová M. (Brno) a spol.	Optické mapování genomu akutních myeloidních leukémií (AML): nové pohledy na strukturní varianty a jejich klinický význam	XXXV. Izakovičov memoriál 2025

AKUTNÍ MYELOIDNÍ LEUKÉMIE II. (Postery P20 - P27)

P20	Kuželová K. (Praha) a spol.	SQSTM1/p62 Inhibition Impairs Mitophagy and Cellular Respiration in AML Cells	Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment
P21	Wolfová K. (Praha) a spol.	Common features of stress response to drugs targeting the nucleus and mitochondria	ESHAML2025

P22	Nemes D. (Praha) a spol.	Redox Dependency and Antioxidant Vulnerability in MLL-Rearranged Leukemia	
P23	Beránková M. (Hradec Králové) a spol.	APL-Like Acute Myeloid Leukemia With KMT2A-PTD and MYC Amplification in an Elderly Patient: A Case Report	
P24	Röselová P. (Praha) a spol.	Perfusion model of microvascular endothelium activation by AML-derived secreted factors	
P25	Štach M. (Praha) a spol.	CD123-specific CAR-T cells produced by Linear DNA-based piggyBac transposon system – initiation of phase I clinical trial in patients with AML	<i>EHA 2025</i>
P26	Jindra P. (Plzeň) a spol.	DETERMINANTS OF OUTCOMES AFTER ALLOGENEIC TRANSPLANTATION (ALLOHCT) IN PATIENTS ≥70 YEARS OF AGE – SINGLE CENTRE ANALYSIS	<i>EBMT 2025</i>
P27	Dobrovolná M. (Praha) a spol.	The Transplant Program Quality Council meetings as the effective tool for the QMS introduction and maintenance and the implementation of new requirements	<i>EBMT 2025</i>

CHRONICKÁ MYELOIDNÍ LEUKÉMIE (Postery P28 - P34)

P28	Čuřík N. (Praha) a spol.	Ponatinib-based Combination Therapies Including Asciminib and Venetoclax Were Effective on Patient-derived Xenograft Models of Chronic Myeloid Leukemia in Blast Phase	<i>ASH 2025</i>
P29	Burda P. (Praha) a spol.	Allele-dependent activity of promoters of genes SLC22A4 and SLC22A5 encoding imatinib transporters in chronic myeloid leukemia blast cells	<i>ASH 2025</i>
P30	Kašša S. (Brno) a spol.	Residual normal hematopoietic stem cells predict early hematological toxicity in chronic myeloid leukemia	<i>EHA 2025</i>
P31	Žižková H. (Praha) a spol.	Evaluating reverse transcriptase efficiency in CML: Consequences for deep molecular response classification and treatment-free remission decisions	<i>ASH 2025</i>
P32	Dvořáček L. (Praha) a spol.	Functional analysis of a novel germline JAK2 variant associated with thrombocytosis	<i>ne</i>

P33	Zimolová V. (Praha) a spol.	Functional Characterization of a Novel Germline JAK2 R989fs Mutation	ASH 2025
P34	Žáčková D. (Brno) a spol.	Designing and testing a CML Quality of Life Tracker, a digital solution to facilitate effective and consistent communication between patients with CML and healthcare providers regarding the impact on their daily life	ESH-ICMLf 27th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
Lymfomy I (P35 - P45)			
P35	Belada D. (Hradec Králové) a spol.	Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from EPCORE NHL-2 arms 6 and 7	ASH 2025
P36	Belada D. (Hradec Králové) a spol.	Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: results from the EPCORE NHL-2 trial	ASH 2025
P37	Belada D. (Hradec Králové) a spol.	Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: results from the EPCORE NHL-2 trial	ASH 2025
P38	Belada D. (Hradec Králové) a spol.	Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: results from EPCORE DLBCL-3	ASH 2025
P39	Belada D. (Hradec Králové) a spol.	Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): long-term data reinforce clinical potential of the regimen across a diverse patient population	ASH 2025
P40	Vodička P. (Praha) a spol.	Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma	ASH 2025
P41	Vodička P. (Praha) a spol.	Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-miniCHOP	ASH 2025
P42	Vodička P. (Praha) a spol.	Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma	ASH 2025
P43	Vodička P. (Praha) a spol.	Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis	ASH 2025

P44	Vodička P. (Praha) a spol.	Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation	ASH 2025
P45	Vodička P. (Praha) a spol.	FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis	ASH 2025
Lymfomy II (P46 - P56)			
P46	Trněný M. (Praha) a spol.	First disclosure of epcoritamab + R-ICE in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (ASCT): EPCORE NHL-2	EHA 2025; SOHO 2025
P47	Marečková A. (Brno) a spol.	Diagnosticky opomíjené defekty negativně ovlivňující prognózu a přežití pacientů s difúzním velkobuněčným B-lymfomem	ne
P48	Hamová I. (Praha, Vestec) a spol.	Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation	ASH 2025
P49	Hanáčková V. (Olomouc) a spol.	Frontline Regimens and Consolidation in PMBCL: A Pooled Real-World Analysis from the Mayo Clinic and CLSG	
P50	Maláriková D. (Praha) a spol.	Four cycles of R-CHOP show the same effectivity as six cycles in real-world DLBCL patients with localized, non-bulky disease independently of other unfavourable risk factors	EHA 2025
P51	Rajmonová A. (Praha) a spol.	Cell Cycle Dependent and Independent Regulation of AKT Activity in Germinal Center B-cell-like Diffuse Large B-cell lymphoma – a Dual Role of Cyclin Dependent Kinase 2	ASH 2025
P52	Heřman V. (Praha) a spol.	Phosphoinositide dependent protein kinase 1 is a key metabolic regulator and potential therapeutic target in lymphoma	ICML Lugano 2025
P53	Navrkalová V. (Brno) a spol.	Targeted Gene Expression Profiling for Rapid ABC/GCB Stratification of DLBCL Patients: Evaluating the Prognostic and Predictive Impact of COO Subtyping	ISLH 2025
P54	Mociková H. (Praha) a spol.	The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial	ICML 2025

P55	Masár M. (Praha) a spol.	Comparable PFS in isolated parenchymal CNS vs systemic relapse of DLBCL: Results from a large real-world cohort	ASH 2025
P56	Hricko S. (Brno) a spol.	Impact of Primary CNS Prophylaxis in High CNS-IPI DLBCL: Analysis from the Czech National Lymphoma Registry	ASH 2025
Lymfomy III (P57 - P64)			
P57	Hájek M. (Brno) a spol.	Vitamin D and Other Micronutrients Influence Prognosis of Patients with Non-Hodgkin lymphoma (NHL).	ASH 2025
P58	Šimkovič M. (Hradec Králové) a spol.	Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter Transformation (RT): first results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial	ASH 2025
P59	Malčíková J. (Brno) a spol.	Clonal shifts of TP53 mutations in patients treated with BTK and BCL2 inhibitors: analysis of accompanying genomic changes	iwCLL2025
P60	Mikulová A. (Brno) a spol.	Casein kinase 1δ/ε inhibition mediates chronic lymphocytic leukemia suppression by a combination of cell cycle block and decreased response to microenvironmental stimuli	MILESTONE International Conference CK1
P61	Mihályová J. (Ostrava) a spol.	Measurable Residual Disease in Chronic Lymphocytic Leukemia (CLL) in Clinical Practice: A Single-Center Report Over the Years 2018–2024	IWCLL2025
P62	Plevová, Karla (id: 97)	Clonality assessment in multiclonal chronic lymphocytic leukemia using Sanger and next-generation sequencing approaches	iwCLL - International Workshop on Chronic Lymphocytic Leukemia
P63	Kaščák M. (Ostrav) a spol.	Validation of Novel Prognostic Models in Symptomatic Waldenström's Macroglobulinemia Based on Real-World Data	ASH 2025
P64	Turcsanyi P. (Olomouc) a spol.	Leukémie z velkých granulárních lymfocytů, zkušenosti pracoviště	ne
Myelomy (P65 - P73)			

P65	Žihala D. (Ostrava) a spol.	Circulating tumor cells for the staging of multiple myeloma: a European pooled analysis of 2446 newly diagnosed patients	EHA 2025
P66	Venglář O. (Ostrava) a spol.	High-Dimensional Profiling Reveals Predominant Depletion of NK Cell Effector Phenotypes in Relapsed/Refractory Multiple Myeloma Patients Treated with anti-CD38 Therapy	ASH 2025
P67	Bílek D. (Ostrava) a spol.	Biology of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): Comparative Transcriptomic Profiling Reveals Egression-Associated Changes Related to CTC Burden	ASH 2025
P68	Žihala D. (Ostrava) a spol.	Selective depletion of B-cell lineage subsets during treatment with anti-BCMA vs anti-GPRC5D bispecific antibodies (bsAbs) underlies different risk of infections in patients with multiple myeloma (MM)	EHA 2025
P69	Štork M. (Brno) a spol.	Genomic landscape of para-skeletal and extramedullary plasmacytomas in multiple myeloma patients	EHA 2025
P70	Popková T. (Ostrava) a spol.	A Multicenter Phase 2 Study Designed to Optimize the Schedule of Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma	EHA 2025
P71	Menšíková K. (Brno) a spol.	De-escalated Teclistamab Dosing in Relapsed/Refractory Multiple Myeloma: Czech Myeloma Group Real-World Evidence Study	EHA 2025
P72	Popková T. (Ostrava) a spol.	CHARACTERIZATION OF OPHTHALMIC EXAMINATION FINDINGS (OEFS) AND IMPACT ON READING AND DRIVING IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF)	EHA 2025
P73	Minařík J. (Olomouc) a spol.	Evolution of Myeloma Bone Disease Over Time: Comparison of Selected Biomarkers in MGUS, SMM and active MM	ASH 2025
Vzácná krevní onemocnění (P74 - P79)			
P74	Peterková L. (Praha) a spol.	Prime editing-mediated correction of FANCA mutation in primary cells from Fanconi anemia patients	Genome Engineering: CRISPR Frontiers
P75	Dulla D. (Praha) a spol.	Hepatitis-Associated vs Idiopathic Paediatric Aplastic Anaemia: Clonal Architecture and Disease Trajectory	EWOG MDS/SAA 2025

P76	Červínek L. (Brno) a spol.	Fostamatinib přináší nové možnosti kombinační léčby pacientů s imunitními cytopeniemi	
P77	Dostálová Merkerová M. (Praha) a spol.	Metabolic consequences of distinct SF3B1 mutations in myelodysplastic neoplasms	<i>4th Prague Symposium on Cancer Metabolism</i>
P78	Pinc Z. (Praha) a spol.	Altered T Cell Bioenergetics in Hypoplastic Myelodysplastic Neoplasms and Idiopathic Aplastic Anemia	<i>The 18th International Congress on MDS</i>
P79	Kriegler T. (Chrudim) a spol.	Etiologie a léčba splanchnické trombózy ve východních Čechách	
Experimentální a translační hematologie (Postery P80 - P84)			
P80	Grusanovic S. (Praha) a spol.	Chronic inflammation drives HSC aging, clonal expansion, and altered infection response in mice	<i>EHA-SWG Scientific Workshop on From Aging Hematopoietic Stem Cells to Age-related Diseases</i>
P81	Seňavová J. (Praha) a spol.	Polatuzumab Vedotin Induced Activation of B-cell Receptor Signaling Creates a Synthetic Lethality with BTK and AKT Inhibition in Mantle Cell Lymphoma	<i>ASH 2025</i>
P82	Ribeiro Bas I. (Praha) a spol.	C/EBPδ preserves hematopoietic stem homeostasis and regulates myeloid commitment in a context-dependent manner	<i>EHA Recon 2025</i>
P83	Reiterová M. (Praha) a spol.	Novel EuroFlow Quality Assessment on B-cell Precursor Acute Lymphoblastic Leukemia Minimal Residual Disease. Program development and Four Rounds of Implementation	<i>EHA 2025</i>
P84	Stefflová L. (Praha) a spol.	Chimerism analysis after allogeneic hematopoietic stem cell transplantation: clinical relevance and methodology	<i>38th European Immunogenetics & Histocompatibility Conference</i>